Dopamine agonist withdrawal syndrome: Implications for patient care

Drugs and Aging

Volumn 30, Issue 8, 2013, Pages 587-592

  Nirenberg, Melissa J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AGITATION; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BRAIN DEPTH STIMULATION; CONFUSION; DEPRESSION; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DISTRESS SYNDROME; DOPAMINE AGONIST WITHDRAWAL SYNDROME; DOSE RESPONSE; DYSPHORIA; FATIGUE; FLUSHING; HUMAN; IMPULSE CONTROL DISORDER; INSOMNIA; IRRITABILITY; MOTOR DYSFUNCTION; NAUSEA; OCCUPATIONAL DISEASE; ORTHOSTATIC HYPOTENSION; PAIN; PANIC; PARKINSON DISEASE; PATIENT CARE; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESTLESS LEGS SYNDROME; SOCIAL DISABILITY; STEREOTYPY; SUICIDAL IDEATION; VOMITING; WITHDRAWAL SYNDROME;

ANTIPARKINSON AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; PROGNOSIS; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84880811780     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0090-z     Document Type: Article

References (23)

1. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2008;2:CD006564.
2. Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. Neurodegener Dis. 2013;11(2):63-71.
3. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging. 2010;27(4):295-310.
4. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-95.
5. Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. 2009;25(3):425-31.
6. Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179-81.
7. Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.
8. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30(5):249-55.
9. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524-9.
10. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003;61(3):422-3.
11. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58-63.
12. Sadock BJ, Kaplan HI, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Wolter Kluwer/Lippincott Williams & Wilkins; 2007.
13. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130-5.
14. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord. 2013;28(3):327-33.
15. Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, et al. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience. Int J Neurosci. 2012;122(3):145-53.
16. Nirenberg MJ. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. Brain. 2010;133(11):e155. author reply e6.
17. Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(9):1051-2.
18. Dorfman BJ, Nirenberg MJ. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism Relat Disord. 2013;19(2):269-70.
19. Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson's disease. Parkinsonism Relat Disord. 2012;18(4):377-81.
20. MacMahon MJ, MacMahon DG. Management of Parkinson's disease in the acute hospital environment. J R Coll Physicians Edinb. 2012;42(2):157-62.
21. Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc). 2010;46(7):483-505.
22. Schupbach M, Gargiulo M, Welter ML, Mallet L, Behar C, Houeto JL, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology. 2006;66(12):1811-6.
23. Gilbert F. The burden of normality: from 'chronically ill' to 'symptom free'. New ethical challenges for deep brain stimulation postoperative treatment. J Med Ethics. 2012;38(7):408-12.